TNBC has the worst prognosis among all breast cancer subtypes2 and, unlike other breast cancer subtypes (Luminal A, Luminal B, and HER2), the lack of these three receptors makes its treatment especially challenging, as these receptors normally serve as therapeutic targets3. This evidence concerns the gene ERBB2 and breast cancer.